StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.08−0.27 (-20.00%)

Close on Nov 18, 2026Market cap $33.96MP/E 3.0Yield –

Actinium Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Actinium Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $9.56M. For fiscal 2025 it was -$36.25M. The highest annual figure on record is -$26.05K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.25M–
FY2024Dec 31, 2024-$42.12M–
FY2023Dec 31, 2023-$51.92M–
FY2022Dec 31, 2022-$34.10M–
FY2021Dec 31, 2021-$24.96M–
FY2020Dec 31, 2020-$22.39M–
FY2019Dec 31, 2019-$22.07M–
FY2018Dec 31, 2018-$23.83M–
FY2017Dec 31, 2017-$26.91M–
FY2016Dec 31, 2016-$26.85M–
FY2015Dec 31, 2015-$24.83M–
FY2014Dec 31, 2014-$22.48M–
FY2013Dec 31, 2013-$6.59M–
FY2012Dec 31, 2012-$7.95M–
FY2011Dec 31, 2011-$3.28M–
FY2010Dec 31, 2010-$26.05K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$27.57M–
Q1 FY2026Mar 31, 2026-$5.90M–
Q4 FY2025Dec 31, 2025-$6.41M–
Q3 FY2025Sep 30, 2025-$5.69M–
Q2 FY2025Jun 30, 2025-$7.50M–
Q1 FY2025Mar 31, 2025-$16.64M–
Q4 FY2024Dec 31, 2024-$7.51M–
Q3 FY2024Sep 30, 2024-$12.60M–
Q2 FY2024Jun 30, 2024-$12.42M–
Q1 FY2024Mar 31, 2024-$9.60M–
Q4 FY2023Dec 31, 2023-$10.34M–
Q3 FY2023Sep 30, 2023-$14.35M–
Q2 FY2023Jun 30, 2023-$15.64M–
Q1 FY2023Mar 31, 2023-$11.58M–
Q4 FY2022Dec 31, 2022-$11.29M–
Q3 FY2022Sep 30, 2022-$9.80M–
Q2 FY2022Jun 30, 2022-$7.85M–
Q1 FY2022Mar 31, 2022-$5.16M–
Q4 FY2021Dec 31, 2021-$8.05M–
Q3 FY2021Sep 30, 2021-$6.47M–
Q2 FY2021Jun 30, 2021-$5.08M–
Q1 FY2021Mar 31, 2021-$5.37M–
Q4 FY2020Dec 31, 2020-$6.44M–
Q3 FY2020Sep 30, 2020-$5.61M–
Q2 FY2020Jun 30, 2020-$4.66M–
Q1 FY2020Mar 31, 2020-$5.68M–
Q4 FY2019Dec 31, 2019-$4.63M–
Q3 FY2019Sep 30, 2019-$6.65M–
Q2 FY2019Jun 30, 2019-$5.09M–
Q1 FY2019Mar 31, 2019-$5.70M–
Q4 FY2018Dec 31, 2018-$6.36M–
Q3 FY2018Sep 30, 2018-$6.20M–
Q2 FY2018Jun 30, 2018-$4.91M–
Q1 FY2018Mar 31, 2018-$6.35M–
Q4 FY2017Dec 31, 2017-$5.21M–
Q3 FY2017Sep 30, 2017-$6.70M–
Q2 FY2017Jun 30, 2017-$7.20M–
Q1 FY2017Mar 31, 2017-$7.81M–
Q4 FY2016Dec 31, 2016-$6.83M–
Q3 FY2016Sep 30, 2016-$7.10M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?